Sutent 12.5 mg Capsule

Sutent 12.5 mg Capsule

Product Description:

Sutent 12.5 mg Capsule is an oral targeted cancer therapy medication used in the treatment of various advanced or metastatic cancers. It contains Sunitinib, a multi-targeted receptor tyrosine kinase (RTK) inhibitor, which works by blocking the signals that promote the growth of cancer cells and the formation of new blood vessels (angiogenesis) that tumors need to grow.

It is commonly used in the treatment of:

• Advanced renal cell carcinoma (kidney cancer)

• Gastrointestinal stromal tumors (GIST) after disease progression or intolerance to imatinib

• Pancreatic neuroendocrine tumors (pNETs)

Mechanism of Action:

Sunitinib inhibits multiple receptor tyrosine kinases involved in tumor proliferation and angiogenesis, including VEGFR, PDGFR, KIT, and FLT3.

Key Features:

• Targeted therapy with proven efficacy in multiple tumor types

• Convenient once-daily oral capsule

• Supplied in bottle packaging of 30 capsules

• Widely exported for clinical use in oncology centers